Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model.

Reproductive sciences (Thousand Oaks, Calif.) - 1 Mar 2022

Garcia Natalia, Ulin Mara, Ali Mohamed, Al-Hendy Ayman, Carvalho Katia Candido, Yang Qiwei

Abstract excerpt

Uterine leiomyosarcoma (LMS) contributes to a significant proportion of uterine cancer deaths. It is a rare and high-risk gynecological cancer. LMS is challenging to the treatment due to the resistance of several therapies. The activation of the Hedgehog (HH) pathway has been reported in several types of female cancers. Uterine LMS presents an upregulation of the crucial HH signaling pathway members such as SMO...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hedgehog Proteins
Share to Biphenyl Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leiomyosarcoma

Share to Mice, Nude

Share to Pyridines

Share to Pyrimidines

Share to Uterine Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34642915
DOI: 10.1007/s43032-021-00731-y
PMCID: PMC8863774

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model.PMID 34642915Read ↗

Targeting Hedgehog pathway and DNA methyltransferases suppress the phenotype of uterine leiomyosarcoma cellsSemantic proximity Read ↗

Patient-derived xenograft studies of fumarate hydratase (FH)-deficient uterine leiomyoma subtypeSemantic proximity Read ↗

Hedgehog pathway inhibitors: a patent review (2009 – present)Semantic proximity Read ↗

Anti-miRNA therapeutics for uterine fibroidsSemantic proximity Read ↗

Beyond cyclopamine: Targeting Hedgehog signaling for cancer interventionSemantic proximity Read ↗

MiR-142-3p could serve as a potential biomarker for individualized treatment of solitary and multiple leiomyomasSemantic proximity Read ↗

Design of Hedgehog pathway inhibitors for cancer treatmentSemantic proximity Read ↗

Hhip regulates tumor-stroma-mediated upregulation of tumor angiogenesis.Semantic proximity Read ↗

NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.Semantic proximity Read ↗

miR-636 inhibits EMT, cell proliferation and cell cycle of ovarian cancer by directly targeting transcription factor Gli2 involved in Hedgehog pathwaySemantic proximity Read ↗

Hedgehog pathway and cancer: A new area (Review).Semantic proximity Read ↗

Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall SurvivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.